Explore the Global FcRn Inhibitors Market — analysis of key trends, regional growth, top players, and a 10-year forecast from 2026 to 2036

Future Market Insights

FcRn Inhibitors Market

Key Insight

FcRn inhibitors sales will expand through 2036, with efgartigimod holding 65.4% of the drug type segment in 2026. The market was valued at USD 2.36 billion in 2025 and is expected to be worth USD 3.49 billion by 2036, creating an incremental opportunity of USD 1.04 billion between 2026 and 2036.

May 22, 2026

Anurag Sharma

250 Pages

Cite this Report

FcRn Inhibitors Market

https://www.futuremarketinsights.com/reports/fcrn-inhibitors-market

License

Starting at US$ 5000

Buy Now

Summary ToC Infographics Companies

Key Players

Argenx SE
HanAll Biopharma/Harbour BioMed
UCB Pharma Limited
Viridian Therapeutics

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

FcRn Inhibitors Market

Key Players

Similar Industry Reports